Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Divestments (2016 - 2025)

Historic Divestments for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to $1.3 million.

  • Gsk's Divestments rose 11036.25% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$35.9 million, marking a year-over-year decrease of 2233.16%. This contributed to the annual value of -$35.6 million for FY2025, which is 5474.74% down from last year.
  • Per Gsk's latest filing, its Divestments stood at $1.3 million for Q4 2025, which was up 11036.25% from $1.3 million recorded in Q3 2025.
  • In the past 5 years, Gsk's Divestments registered a high of $80.1 million during Q2 2023, and its lowest value of -$37.4 million during Q2 2025.
  • Its 5-year average for Divestments is -$1.0 million, with a median of -$5.6 million in 2023.
  • Over the last 5 years, Gsk's Divestments had its largest YoY gain of 61144.65% in 2023, and its largest YoY loss of 64351.35% in 2023.
  • Gsk's Divestments (Quarter) stood at -$25.6 million in 2021, then soared by 45.05% to -$14.1 million in 2022, then surged by 611.45% to $72.0 million in 2023, then crashed by 117.83% to -$12.8 million in 2024, then skyrocketed by 110.36% to $1.3 million in 2025.
  • Its Divestments was $1.3 million in Q4 2025, compared to $1.3 million in Q3 2025 and -$37.4 million in Q2 2025.